Note: results can be filtered by year and/or keyword. To filter on year, select the appropriate year from the drop down menu. To filter on keyword, enter relevant term into open box, select appropriate keyword, and click "filter".
Reports & Briefings
The 2015 Out of Step report will be published and available here on 2 December, 2015.
Last updated 24 November 2015
The challenge of antimicriobial resistance
Last updated 16 November 2015
The IPR Think Tank was convened in November 2014 by Department of Industrial Policy & Promotion, Ministry of Commerce, Government of India, to draft a national IPR Policy for India. A particular area of concern for health groups is IP policy making that impacts the pharmaceutical sector, as India is a key global supplier of affordable generic versions of drugs that otherwise would be out of reach for public health programmes, treatment providers and millions of people.
Last updated 6 November 2015
Tuberculosis (TB) mainly affects low- and middle- income countries with 95% of cases occurring there. 1.3 million people were killed by the disease in 2012 and there were 8.6 million new cases requiring treatment. With the advent of new diagnostics like GeneXpert the confirmed numbers of multidrug-resistant (MDR) TB cases are rising and programmes are unable to cope - 16,000 patients diagnosed with MDR-TB in 2012 did not receive treatment. And about 80% of those estimated to have MDR-TB are not even diagnosed.
Last updated 31 October 2015
Review of the European Union’s Trade & Investment Policy.
Last updated 14 October 2015
Brazil is one of many governments working to strike a balance between public and private interests in determining how medical innovation is conducted and incentivised – and how medical products and technologies can be made accessible for the benefit of public health. At this point, several bills and recommendations have been tabled in the Brazilian Congress.
Last updated 8 September 2015
An estimated five million people around the world are bitten by venomous snakes every year. Snakebite kills as many as 100,000 people and leads to disability and disfiguration for some 400,000 victims globally each year. Most of the victims come from remote, rural areas. With no health facilities nearby, and unable to afford expensive treatment, many either forego treatment completely or turn to traditional healers.
Last updated 7 September 2015
Snakebite is a neglected health issue which kills anywhere from 20,000 to 95,000 people globally each year. In sub-Saharan Africa, it is estimated that between 4,000 and 30,000 people die per year. In 2010, Sanofi made the internal decision to stop production of Fav-Afrique, a highly effective and affordable antivenom. In January 2014, the last batch of Fav-Afrique was produced and very quickly sold out, leading to a shortage. The expiry date – or the end of the shelf life – for the last batch of Fav-Afrique produced is June 2016.
Last updated 7 September 2015
The global response to HIV/AIDS is neglecting crucial but underfunded resources necessary to keeping millions on lifelong, daily care, especially in Sub-Saharan Africa that has the double challenge of addressing high HIV and TB burdens with the lowest number of health care workers, the international humanitarian organization Médecins Sans Frontières/Doctors Without Borders (MSF) said ahead of the IAS conference on HIV pathogenesis, treatment and prevention.
Last updated 20 July 2015
A product guide for point-of-care CD4 and laboratory-based and point-of-care virological HIV and HCV tests This product guide is for policymakers, treatment providers and advocates interested in learning more about laboratory-based and point-of-care virological HIV and hepatitis C (HCV), and point-of-care CD4, diagnostic and monitoring tests. DOWNLOAD THE REPORT
Last updated 15 July 2015